22 completed, 4 recruiting, 4 terminated, 3 unknown. 38 Phase 2, 6 Phase 1, 3 Phase 3.
Follow Essential Tremor: new trials by email Literature Review of Essential Tremor trials Research Report on Essential Tremor
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Motor and Non-Motor Effects of Low-Intensity Focused Ultrasound (LIFU) as a Neuromodulation Tool in Essential Tremor Low-Intensity Focused Ultrasound (LIFU) - NeuroFUS PRO - Essential Tremor (ET) | Phase 1 / Phase 2 | Not yet recruiting | University of Sao Paulo General Hospital | 20 | 2026-03-17 | 2026-03-19 |
| Dual-Site Transcranial Magnetic Stimulation of the Supplementary Motor Area and Cerebellum for the Treatment of Essential Tremor. Dual-site repetitive transcranial magnetic stimulation (rTMS) of the supplementary motor area and cerebellum, Transcranial Magnetic Stimulation Sham - Essential Tremor | Phase 1 / Phase 2 | Recruiting | São Paulo State University | 36 | 2026-01-15 | 2026-01-21 |
| Proof of Concept Study on BP1.4979 Effect on Essential Tremor BP1.4979, Placebo - Essential Tremor | Phase 2 | Recruiting | Bioprojet | 50 | 2025-09-17 | 2025-12-16 |
| Developing a New LIFU Neuromodulation Method to Suppress Tremor Transcranial focused ultrasound stimulation, Sham stimulation - Essential Tremor | Phase 2 | Not yet recruiting | University of Calgary | 20 | 2025-09-15 | 2025-08-05 |
| Stereotactic Radiosurgery in the Treatment of Essential Tremor Stereotactic Radiosurgery - Essential Tremor | Phase 2 | Recruiting | Maria Sklodowska-Curie National Research Institute of Oncology | 42 | 2024-12-16 | 2026-10-20 |
| A Study to Evaluate the Long-term Safety and Tolerability of SAGE-324 in Participants With Essential Tremor SAGE-324 - Essential Tremor | Phase 2 / Phase 3 | Terminated | Sage Therapeutics | 97 | 2022-06-03 | 2025-08-01 |
| A Clinical Trial of PRAX-114 in Participants With Essential Tremor 10 mg PRAX-114, 20 mg PRAX-114, and Placebo, 10 mg PRAX-114 or 20 mg PRAX-114 - Essential Tremor | Phase 2 | Withdrawn | Praxis Precision Medicines | 2022-04-05 | 2022-11-30 | |
| Study to Evaluate SAGE-324 in Participants With Essential Tremor SAGE-324, SAGE-324 Matched Placebo - Essential Tremor | Phase 2 | Completed | Sage Therapeutics | 146 | 2022-01-05 | 2025-05-16 |
| A Study To Assess the Safety and Efficacy of JZP385 in the Treatment of Adults With Moderate to Severe Essential Tremor (ET) JZP385, Placebo - Essential Tremor | Phase 2 | Completed | Jazz Pharmaceuticals | 420 | 2021-12-06 | 2025-07-24 |
| Efficacy, Safety, and Pharmacokinetics of ES-481 in Adult Patients With Essential Tremors ES-481, Placebo - Tremor, Essential | Phase 2 | Unknown | ES Therapeutics Australia Pty Ltd | 24 | 2021-11-21 | 2023-03-02 |
| A Clinical Trial of 2 Doses of PRAX-944 in Participants With Essential Tremor 100 mg PRAX-944, 60 mg PRAX-944, Placebo - Essential Tremor | Phase 2 | Completed | Praxis Precision Medicines | 133 | 2021-10-14 | 2024-03-13 |
| Linac FRACtionated Radiosurgical THALamotomie in Tremors (FRACTHAL) Radiosurgical thalamotomy on GammaKnife - Essential Tremor, Parkinsonian Disorders | Phase 2 | Terminated | Centre Hospitalier Universitaire de Nice | 9 | 2021-07-01 | 2026-05-26 |
| Bilateral Essential Tremor Treatment With Gamma Knife Gamma Knife VIM thalamotomy - Essential Tremor | Phase 2 / Phase 3 | Recruiting | Université de Sherbrooke | 50 | 2021-06-08 | 2021-11-17 |
| Safety, Efficacy, and Tolerability of NBI-827104 for the Treatment of Essential Tremor NBI-827104, Placebo - Essential Tremor | Phase 2 | Completed | Neurocrine Biosciences | 31 | 2021-04-20 | 2022-07-12 |
| A Study to Evaluate the Efficacy, Safety, and Tolerability of SAGE-324 in Participants With Essential Tremor SAGE-324, SAGE-324 Placebo - Essential Tremor | Phase 2 | Completed | Sage Therapeutics | 69 | 2020-05-19 | 2024-04-17 |
| A Clinical Trial of PRAX-944 in Participants With Essential Tremor Part A: 20 and 40 mg PRAX-944, Part B: 120 mg PRAX-944, Part B: 120 mg PRAX-944 and Placebo - Essential Tremor | Phase 2 | Completed | Praxis Precision Medicines | 24 | 2020-03-03 | 2024-03-01 |
| A Clinical Study to Evaluate CAD-1883 in Essential Tremor CAD-1883 - Essential Tremor | Phase 2 | Completed | Cadent Therapeutics | 25 | 2019-01-23 | 2021-08-05 |
| Trial of Cannabis for Essential Tremor CBD/THC, Placebo oral capsule - Essential Tremor | Phase 1 / Phase 2 | Completed | University of California, San Diego | 7 | 2019-01-22 | 2022-10-13 |
| tSMS in Essential Tremor tSMS, sham - Essential Tremor | Phase 2 | Completed | Fundación de investigación HM | 30 | 2018-10-01 | 2022-06-06 |
| A Phase 2 RCT Study of CX-8998 for Essential Tremor CX-8998, Placebo - Essential Tremor | Phase 2 | Completed | Jazz Pharmaceuticals | 95 | 2017-08-29 | 2021-11-23 |
Showing 20 of 38. Sign in to see all of them.
Movement Disorders (13) · Tremor (10) · Central Nervous System Diseases (2) · Parkinson Disease (2) · Dyskinesias (1) · Dysphonia (1) · Dystonia (1) · Nervous System Diseases (1) · Neurologic Manifestations (1) · Parkinsonian Disorders (1) · Voice Disorders (1)
Nervous System Diseases (37) · Central Nervous System Diseases (36) · Movement Disorders (25) · Pathological Conditions, Signs and Symptoms (11) · Signs and Symptoms (11) · Dyskinesias (10) · Neurologic Manifestations (10) · Basal Ganglia Diseases (3) · Brain Diseases (3) · Neurodegenerative Diseases (2) · Parkinsonian Disorders (2) · Synucleinopathies (2) · Laryngeal Diseases (1) · Otorhinolaryngologic Diseases (1) · Respiratory Tract Diseases (1)
1-Octanol (2) · octanoic acid (2) · Acamprosate (1) · Botulinum Toxins, Type A (1) · Cannabidiol (1) · Dexmedetomidine (1) · Dronabinol (1) · Levetiracetam (1) · Methazolamide (1) · Radiosurgery (1) · S-2-O-carbamoyl-1-o-chlorophenyl-ethanol (1) · Saline Solution (1) · Sodium Oxybate (1) · Transcranial Magnetic Stimulation (1) · Zonisamide (1)
Sage Therapeutics (4) · Jazz Pharmaceuticals (3) · National Institute of Neurological Disorders and Stroke (NINDS) (3) · Praxis Precision Medicines (3) · Sun Pharmaceutical Industries, Inc. (2) · VA Greater Los Angeles Healthcare System (2) · Biogen (1) · Bioprojet (1) · Cadent Therapeutics (1) · Centre Hospitalier Universitaire de Nice (1) · ES Therapeutics Australia Pty Ltd (1) · Fundación de investigación HM (1) · Henry Ford Health System (1) · Maria Sklodowska-Curie National Research Institute of Oncology (1) · Neurocrine Biosciences (1)
United States (23) · Canada (6) · Australia (2) · Poland (2) · Spain (2) · Brazil (1) · France (1) · Germany (1) · Monaco (1) · Netherlands (1) · New Zealand (1)
Aaron Ellenbogen, DO (1) · Adrian Handforth, M.D. (1) · Aleksandra Napieralska (1) · Charles A Handforth, M.D. (1) · Christopher Lind, MBChB, FRACS (1) · Fatta Nahab, MD (1) · Joseph Neimat, M.D. (1) · Mandar Jog, MD (1) · Peter LeWitt, M.D. (1) · Robert Lasser, MD, MBA (1)
PMID 21594724, PMID 14718713, PMID 15210907, PMID 20201005, PMID 22454323, PMID 23408867, PMID 31244760, PMID 41298510
R03DC012429 (1)